Precision Biosciences (DTIL) Operating Expenses (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Operating Expenses of $19.9 million for Q1 2026, down 10.06% year-over-year from $22.1 million in Q1 2025, and down 8.22% quarter-over-quarter from $21.7 million in Q4 2025.
Precision Biosciences (DTIL) Operating Expenses (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Operating Expenses for 9 consecutive years, with $19.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 10.06% year-over-year to $19.9 million; the TTM figure through Mar 2026 stood at $84.2 million (down 11.6% YoY), while the FY2025 annual figure was $86.4 million, down 8.9% from the prior year.
- Operating Expenses slipped to $19.9 million in Q1 2026 per DTIL's latest filing, from $21.7 million in the prior quarter.
- Across five years, Operating Expenses topped out at $33.4 million in Q2 2022 and bottomed at $19.9 million in Q1 2026.
- Historically, Operating Expenses has averaged $23.7 million across 5 years, with a median of $22.1 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Expenses sank 38.73% — and 2024, when it rose 16.22%.
- Precision Biosciences' Operating Expenses stood at $22.7 million in 2022, then fell by 3.43% to $21.9 million in 2023, then gained by 16.22% to $25.5 million in 2024, then declined by 14.86% to $21.7 million in 2025, then slipped by 8.22% to $19.9 million in 2026.
- Business Quant data shows DTIL's Operating Expenses at $19.9 million in Q1 2026, $21.7 million in Q4 2025, and $20.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.96 Bn | 132.11 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 60.20 Bn | 55.06 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.19 Bn | 37.09 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.43 Bn | 28.12 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 541.02 Mn |
| 10 | Precision Biosciences | 225.73 Mn | 138.18 Mn | - | 19.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.16 Mn |
| Mar 31, 2026 | 19.91 Mn |
| Dec 31, 2025 | 21.70 Mn |
| Sep 30, 2025 | 20.68 Mn |
| Jun 30, 2025 | 21.90 Mn |
| Mar 31, 2025 | 22.14 Mn |
| Dec 31, 2024 | 25.48 Mn |
| Sep 30, 2024 | 21.85 Mn |
| Jun 30, 2024 | 25.75 Mn |
| Mar 31, 2024 | 21.77 Mn |
| Dec 31, 2023 | 21.93 Mn |
| Sep 30, 2023 | 25.48 Mn |
| Jun 30, 2023 | 22.92 Mn |
| Mar 31, 2023 | 22.13 Mn |
| Dec 31, 2022 | 22.71 Mn |
| Sep 30, 2022 | 22.04 Mn |
| Jun 30, 2022 | 33.37 Mn |
| Mar 31, 2022 | 30.65 Mn |
| Dec 31, 2021 | 37.06 Mn |
| Sep 30, 2021 | 35.58 Mn |